SAMSARA BIOCAPITAL, LLC
Long book
$1.03B
Q1 2026
Positions
22
Top-10 weight
92%
concentration
Last quarter
+10.8%
SPY +14.8%
Turnover
21%
of book per quarter
Strategy in plain words
auto-generated from filingsSAMSARA BIOCAPITAL, LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $1.03B US long book across 22 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: SCHOLAR ROCK HOLDING CORP, MINERALYS THERAPEUTICS INC, ALUMIS INC, SEPTERNA INC, KALARIS THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 3.4pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-32.7%
Q2 2024
+0.1%
Q3 2024
+52.0%
Q4 2024
-27.7%
Q1 2025
-7.3%
Q2 2025
+59.5%
Q3 2025
+19.9%
Q4 2025
-3.4%
Q1 2026
+10.8%
Sector allocation
Healthcare 99%
Other 1%
Long book by quarter
What does SAMSARA own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 6.9M | $339.1M | 32.9% | Held |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 5.9M | $159.0M | 15.5% | Held |
| ALMS ALUMIS INC | Healthcare | 6.3M | $139.8M | 13.6% | +10.2% |
| SEPN SEPTERNA INC | Healthcare | 3.1M | $75.7M | 7.4% | Held |
| KLRS KALARIS THERAPEUTICS INC | Healthcare | 12.9M | $74.7M | 7.3% | Held |
| SGP SPYGLASS PHARMA INC | Healthcare | 2.1M | $54.7M | 5.3% | New |
| NGNE NEUROGENE INC | Healthcare | 1.7M | $34.6M | 3.4% | Held |
| STRO SUTRO BIOPHARMA INC | Healthcare | 1.1M | $26.5M | 2.6% | +419.7% |
| JBIO JADE BIOSCIENCES INC | Healthcare | 968.8K | $13.6M | 1.3% | Held |
| VTVT VTV THERAPEUTICS INC- CL A | Healthcare | 298.5K | $11.8M | 1.2% | Held |
| AQST AQUESTIVE THERAPEUTICS INC | Healthcare | 2.5M | $10.4M | 1.0% | Held |
| XFOR X4 PHARMACEUTICALS INC | Healthcare | 1.8M | $7.6M | 0.7% | -6.5% |
| NKTX NKARTA INC | Healthcare | 3.5M | $7.4M | 0.7% | Held |
| ACLXGBX ARCELLX INC | — | 60.9K | $7.0M | 0.7% | Held |
| UPB UPSTREAM BIO INC | Healthcare | 736.0K | $6.6M | 0.6% | Held |
| RANI RANI THERAPEUTICS HOLDINGS-A | Healthcare | 8.5M | $6.2M | 0.6% | Held |
| CHRS COHERUS ONCOLOGY INC | Healthcare | 3.4M | $5.8M | 0.6% | New |
| PVLA PALVELLA THERAPEUTICS INC | Healthcare | 38.4K | $4.8M | 0.5% | -63.3% |
| GOSS GOSSAMER BIO INC | Healthcare | 7.2M | $2.4M | 0.2% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 22 | $1.03B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 21 | $969.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 27 | $765.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 29 | $488.9M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 37 | $560.8M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 43 | $728.6M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 42 | $520.3M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 40 | $477.8M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 39 | $646.4M | canonical | SEC ↗ |